Bengaluru based startup Peptris has raised 7.7 million dollars in a Series A funding round to accelerate its artificial intelligence driven drug discovery efforts. The round was co led by IAN Alpha Fund and Speciale Invest with participation from other investors including Tenacity Ventures and BYT Ventures.
The funding will be used to advance Peptris’s lead programmes toward clinical readiness and expand its discovery pipeline over the next two years. The startup uses a proprietary AI engine to generate novel molecular candidates and predict key drug development parameters early in the research process. This technology is designed to reduce the time and cost traditionally associated with drug discovery while improving the chances of success in later stages of development.
Founded in 2019 by Narayanan Venkatasubramanian, Shridhar Narayanan, Anand Budni and Amit Mahajan, Peptris follows a business to business model by partnering with pharmaceutical and biotechnology companies to co develop programmes and license assets. The company plans to strengthen its teams in biology, chemistry, data science and AI and build business development capabilities in key global markets.
0 Comments